MBX Biosciences Files IPO Amendment

Ticker: MBX · Form: S-1/A · Filed: Aug 30, 2024 · CIK: 1776111

Sentiment: neutral

Topics: ipo, registration, amendment

TL;DR

MBX Biosciences filed an S-1/A for its IPO. Get ready for potential new stock.

AI Summary

MBX Biosciences, Inc. filed an S-1/A amendment on August 30, 2024, for its initial public offering. The company, incorporated in Delaware, is seeking to register an unspecified number of shares. MBX Biosciences, Inc. is located at 11711 N. Meridian Street, Suite 300, Carmel, Indiana 46032, with a phone number of (317) 659-0200.

Why It Matters

This S-1/A filing indicates MBX Biosciences is moving forward with its public offering, which could provide capital for its operations and potentially impact its stock valuation upon listing.

Risk Assessment

Risk Level: medium — As an S-1/A filing, it represents a company seeking to go public, which inherently carries risks associated with market reception and operational execution.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this S-1/A filing?

This is an amendment to the initial S-1 registration statement filed by MBX Biosciences, Inc. for its proposed initial public offering.

When was this amendment filed?

The amendment was filed with the SEC on August 30, 2024.

What is the principal executive office address for MBX Biosciences, Inc.?

The principal executive offices are located at 11711 N. Meridian Street, Suite 300, Carmel, Indiana 46032.

Who is listed as the President and Chief Executive Officer?

P. Kent Hawryluk is listed as the President and Chief Executive Officer of MBX Biosciences, Inc.

Which law firm is listed as providing copies for the filing?

Goodwin Procter LLP is listed as providing copies for the filing.

Filing Stats: 4,389 words · 18 min read · ~15 pages · Grade level 16.8 · Accepted 2024-08-30 17:13:36

Filing Documents

Risk factors

Risk factors 16 Special note regarding forward-looking statements 94

Use of proceeds

Use of proceeds 96 Dividend policy 98 Capitalization 99

Managements discussion and analysis of financial condition and results of operations

Managements discussion and analysis of financial condition and results of operations 104

Business

Business 122 Management 168

Executive compensation

Executive compensation 178 Certain relationships and related person transactions 192 Principal stockholders 197

Description of capital stock

Description of capital stock 200 Shares eligible for future sale 206 Material U.S. federal income tax considerations for non-U.S. holders 208

Underwriting

Underwriting 212 Legal matters 226 Experts 226 Where you can find more information 226 Index to financial statements F-1 We have not, and the underwriters have not, authorized anyone to provide any information or to make any representation other than those contained in this prospectus, any amendment or supplement to this prospectus or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus, any amendment or supplement to this prospectus or any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. i Table of Contents Market data and certain other statistical information used throughout this prospectus are based on independent industry publications, governmental publications, reports by market research firms, or other independent sources that we believe to be reliable sources. Industry publications and third-party research, surv

View Full Filing

View this S-1/A filing on SEC EDGAR

View on Read The Filing